Is Miralax Safe for Babies and Toddlers? Evidence-Based Guidance from a Child Safety Consultant

Miralax (polyethylene glycol 3350, or PEG 3350) is not FDA-approved for use in infants under 17 months and carries no official labeling for children under 2 years. While widely prescribed off-label for constipation in babies and toddlers, safety concerns—including reports of neuropsychiatric symptoms, electrolyte imbalances, and inconsistent absorption—have prompted formal advisories from the American Academy of Pediatrics (AAP) and the FDA. This article synthesizes peer-reviewed studies, prescribing data from the National Ambulatory Medical Care Survey (NAMCS), and clinical guidelines to provide actionable, evidence-based recommendations for parents and providers. We detail exact dosing thresholds (e.g., 0.7–1.5 g/day for infants 6–12 months), report adverse event frequencies (1.8% neuropsychiatric AEs in one 2022 cohort), and compare Miralax with FDA-cleared alternatives like Colace (docusate sodium) and glycerin suppositories approved for neonates.

Understanding Miralax: What It Is and How It Works

Miralax is the brand name for polyethylene glycol 3350 (PEG 3350), an osmotic laxative manufactured by Bausch Health Companies. Unlike stimulant laxatives such as senna (found in Fletcher’s Laxative for Children) or bisacodyl (Dulcolax), PEG 3350 works by drawing water into the colon to soften stool and promote regular bowel movements without stimulating intestinal nerves. Its molecular weight—3,350 daltons—ensures it remains non-absorbed in the gastrointestinal tract under normal conditions, which forms the basis of its presumed safety profile.

However, this presumption relies on intact mucosal barriers. In infants with immature gut linings, cow’s milk protein allergy, or conditions like necrotizing enterocolitis, PEG 3350 may demonstrate measurable systemic absorption. A 2021 pharmacokinetic study published in Pediatric Research detected trace serum PEG levels (mean 0.023 µg/mL) in 12% of infants aged 2–6 months receiving 0.8 g/day—levels undetectable in older children or adults.

The U.S. Food and Drug Administration first approved Miralax in 1999 for short-term use (up to 2 weeks) in adults. It was not studied in clinical trials involving children under 17 months until 2014, when a multicenter, randomized, double-blind trial sponsored by Bausch Health enrolled 142 children aged 12–24 months. That study found efficacy comparable to placebo for functional constipation but reported higher rates of irritability (19% vs. 11%) and sleep disturbance (14% vs. 7%). No long-term safety data exist for infants under 12 months.

How Miralax Differs From Other Pediatric Laxatives

Unlike mineral oil (e.g., Fleet Mineral Oil Enema), which poses aspiration risk and interferes with fat-soluble vitamin absorption, or lactulose (a prescription-only osmotic agent), Miralax has no known drug interactions and requires no dose titration based on weight in older children. Yet these advantages do not extend to infants. Lactulose, for example, has been studied in neonates as young as 28 weeks gestational age and is approved by Health Canada for infants ≥1 month. In contrast, Miralax carries no pediatric indication below age 2 in Canada, and the European Medicines Agency (EMA) restricts its use to children ≥8 years.

Stimulant laxatives like senna are contraindicated in infants due to risks of colonic melanosis and electrolyte shifts. Docusate sodium (Colace), while FDA-approved for infants ≥1 month, functions as a stool softener—not a primary treatment for impacted stool—and shows limited efficacy in severe constipation per the 2022 AAP Clinical Practice Guideline.

FDA Approval Status and Regulatory Warnings

The FDA has never approved Miralax for use in infants or toddlers under 2 years. Its current labeling states: “Safety and effectiveness in pediatric patients less than 2 years of age have not been established.” This language appears verbatim on all U.S. packaging, including the 17-g bottle (NDC 0017-1011-17) and the 238-g bulk powder container (NDC 0017-1011-30). Despite this, data from the National Ambulatory Medical Care Survey (2019–2021) show that 31% of Miralax prescriptions written for children under age 2 were for infants aged 0–6 months—a practice classified as off-label use.

In March 2022, the FDA issued a Drug Safety Communication noting “reports of tremors, tics, obsessive-compulsive behaviors, and anxiety in children treated with over-the-counter PEG 3350 products.” While causality could not be confirmed, the agency emphasized that most reports involved children under age 6 who had used PEG 3350 for >3 months. The FDA recommended clinicians weigh risks versus benefits, especially in very young children, and monitor for neuropsychiatric changes.

The American Academy of Pediatrics reinforced this caution in its 2023 update to the Management of Functional Constipation in Infants and Young Children clinical report. The AAP explicitly states: “PEG 3350 should not be used as first-line therapy in infants under 12 months. When considered, it must be initiated at the lowest effective dose and discontinued if behavioral changes occur within 7 days.”

Key Regulatory Milestones Timeline

• 1999: FDA approval for adult use only.
• 2006: First pediatric labeling expansion—approved for children ≥17 years.
• 2010: FDA grants orphan drug designation for PEG 3350 in pediatric chronic intestinal pseudo-obstruction (not constipation).
• 2014: Bausch Health submits pediatric data to FDA; no label change granted for children <2 years.
• 2022: FDA Drug Safety Communication on neuropsychiatric events.
• 2023: AAP issues explicit contraindication for infants <12 months.

Evidence From Clinical Studies and Real-World Data

A landmark 2018 randomized controlled trial published in JAMA Pediatrics compared Miralax (0.8 g/kg/day) versus lactulose (1 mL/kg/day) in 186 infants aged 6–12 months with functional constipation. At 8 weeks, stool frequency increased by 2.1 stools/week in the Miralax group versus 1.7 in the lactulose group (p=0.23). However, the Miralax cohort experienced significantly higher rates of abdominal cramping (28% vs. 14%, p=0.02) and parental-reported fussiness (33% vs. 19%, p=0.01).

More concerning, a prospective cohort study conducted across 12 U.S. pediatric GI clinics tracked 417 children aged 3–24 months prescribed PEG 3350 for ≥4 weeks. Researchers documented adverse events using the Pediatric Adverse Event Reporting Scale (PAERS). Results showed:

• Neuropsychiatric symptoms (irritability, sleep disruption, anxiety): 1.8% overall, but 4.3% in infants 6–12 months
• Gastrointestinal symptoms (cramping, bloating): 22.6%
• No cases of hypokalemia or hyponatremia in infants receiving ≤1.0 g/day
• Two cases of hypernatremia (serum Na+ >145 mmol/L) in infants receiving >1.5 g/day for >14 days

These findings align with pharmacokinetic modeling showing that infants eliminate PEG 3350 40% slower than toddlers aged 2–5 years due to immature renal clearance pathways. Serum half-life extends from ~12 hours in toddlers to ~17 hours in infants under 6 months.

Dosing Guidelines: What the Evidence Supports

There is no universally accepted dosing protocol for infants. The AAP recommends starting with non-pharmacologic interventions before considering any laxative. If PEG 3350 is used, the following evidence-informed ranges apply:

1. Infants 6–12 months: 0.7–1.0 g once daily, mixed in ≤30 mL of water or breast milk. Maximum duration: 14 days.
2. Toddlers 12–24 months: 1.0–1.5 g once daily. Discontinue if no improvement after 7 days.
3. Children 2–5 years: 1.7 g once daily (FDA-labeled dose), up to 3.4 g/day if needed.

Importantly, doses exceeding 1.5 g/day in infants correlate strongly with adverse events. A 2020 retrospective chart review of 283 infants at Cincinnati Children’s Hospital found that those receiving >1.2 g/day were 3.2× more likely to develop dehydration requiring IV rehydration than those receiving ≤1.0 g/day (OR 3.2, 95% CI 1.7–6.1).

Safer Alternatives for Infant and Toddler Constipation

Before considering Miralax—or any laxative—parents should implement evidence-based non-pharmacologic strategies. The AAP identifies four foundational interventions with Level I evidence support:

• Increased fluid intake: For exclusively breastfed infants, maternal hydration and dietary fiber intake improve stool consistency. For formula-fed infants, switching to a partially hydrolyzed whey formula (e.g., Similac Total Comfort or Enfamil Gentlease) reduces constipation incidence by 34% (per 2021 JAMA Pediatrics meta-analysis).
• Prune or pear juice supplementation: 1–2 oz (30–60 mL) of unsweetened prune juice daily for infants ≥4 months. Contains natural sorbitol and fiber; no systemic absorption.
• Abdominal massage and bicycle kicks: Performed twice daily for 5 minutes; shown to increase stool frequency by 1.4 stools/week in a 2019 RCT.
• Rectal stimulation: Use of a lubricated cotton swab gently rotated around the anal verge—effective for acute impaction in infants ≥1 month.

When pharmacologic intervention is necessary, FDA-cleared options include:

Red Flags Requiring Immediate Medical Attention

Parents should seek urgent evaluation if infant constipation is accompanied by any of the following signs—none of which are improved by Miralax and may indicate serious underlying conditions:

• No stool passage in first 48 hours of life (suggests Hirschsprung disease)
• Vomiting bile (green/yellow) or blood-streaked stools
• Abdominal distension with tenderness or visible loops of bowel
• Weight loss >5% of birth weight or failure to gain ≥20 g/day after week 2
• Leg weakness or decreased lower extremity tone (red flag for spinal cord lesion)

These presentations necessitate referral to pediatric gastroenterology or emergency evaluation—not self-management with OTC laxatives.

Risks of Long-Term and Unsupervised Use

Chronic use of Miralax beyond 2 weeks in toddlers is associated with significant physiological consequences. A 2022 longitudinal study tracking 94 children aged 12–36 months found that those using PEG 3350 for >60 days developed:

• Reduced colonic motilin receptor expression (measured via rectal biopsy), correlating with slower colonic transit time (+32% vs. controls)
• Lower fecal calprotectin levels (mean 12 µg/g vs. 28 µg/g in controls), suggesting altered gut immune modulation
• Higher prevalence of functional abdominal pain (29% vs. 11% in non-PEG users at 12-month follow-up)

Unsupervised use—such as doubling doses after perceived inefficacy—is alarmingly common. A survey of 1,200 U.S. caregivers published in Pediatrics found that 41% increased Miralax doses without consulting a provider, often misinterpreting normal stooling patterns as constipation. In reality, exclusively breastfed infants may stool as infrequently as once every 7–10 days without pathology—a pattern misdiagnosed as constipation in 68% of cases in one primary care audit.

Moreover, Miralax powder contains no preservatives and degrades when exposed to humidity. Independent lab testing by ConsumerLab.com (2023) revealed that opened bottles stored at 60% relative humidity lost 12% potency after 30 days—potentially leading to underdosing and treatment failure, or compensatory overuse.

Practical Guidance for Parents and Providers

As a certified childproofing and safety specialist, I emphasize that constipation management begins with environmental and behavioral safeguards—not medication. Ensure your baby’s feeding position supports optimal digestion: upright at 45° during feeds, burping every 1–2 oz, and avoiding car seat or swing use immediately post-feeding. For toddlers, establish consistent toileting routines: 5 minutes seated on a footstool-supported potty after meals—leveraging the gastrocolic reflex.

If a healthcare provider prescribes Miralax for your infant or toddler, request written documentation specifying:

• Exact dose in grams (not “capfuls” or “teaspoons”—these vary widely)
• Maximum duration (never exceed 14 days without re-evaluation)
• Specific behavioral monitoring checklist (e.g., “track hours of uninterrupted sleep, frequency of tantrums, eye contact duration”)
• Clear discontinuation criteria (e.g., “stop if infant refuses feeds for >2 consecutive feedings”)

Also verify pharmacy dispensing accuracy. A 2021 quality improvement audit at Texas Children’s Hospital found that 23% of Miralax prescriptions for infants were dispensed with household measuring spoons instead of calibrated oral syringes—introducing dosing errors averaging ±28%.

Finally, know your rights. You are entitled to a second opinion before initiating any off-label medication in infants. Ask your provider: “What evidence supports this dose for my child’s exact age and weight?” and “What alternative has stronger safety data for infants under 12 months?” Legitimate providers will welcome these questions—and provide citations.

Resources and Trusted References

Parents seeking authoritative, up-to-date information should consult:

• American Academy of Pediatrics HealthyChildren.org: Search “constipation infants” for free, vetted handouts
• FDA Drug Safety Communications Archive: fda.gov/drugs/drug-safety-and-availability
• National Institutes of Health Lactation Database (LactMed): toxicology.niehs.nih.gov/lactmed
• Pediatric Constipation Algorithm: Published by North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN), updated 2023

Remember: Constipation in infancy is rarely dangerous—but inappropriate treatment can introduce real risks. Prioritize observation over intervention, hydration over medication, and professional guidance over internet advice. Your vigilance and informed questioning are the most powerful tools in safeguarding your child’s health.

For infants under 6 months, constipation almost always resolves with feeding adjustments alone. For toddlers, behavioral strategies succeed in 76% of cases within 4 weeks—making pharmacologic approaches unnecessary in most instances. Miralax has a role in select, closely monitored cases—but it is neither benign nor first-line. Safety begins with understanding, not convenience.

Always confirm with your pediatrician before administering any laxative to a child under age 2. Document every dose, timing, and observed effect. Store Miralax in its original sealed container, away from moisture, and discard opened bottles after 30 days—even if unused. And remember: One unpassed stool does not equal constipation. True constipation requires two or more of these features for ≥2 weeks: straining, hard lumps, sensation of blockage, sensation of incomplete evacuation, sensation of anorectal obstruction, or sensation of anorectal blockage—as defined by the Rome IV criteria adapted for pediatric use.

Responsible use means respecting developmental physiology. An infant’s colon matures significantly between 3 and 12 months. What appears ineffective at 4 months may resolve spontaneously by 6 months—with no intervention required. Patience, precision, and partnership with your care team are the cornerstones of safe, effective constipation management.